Fexofenadine
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Synonyms / Brand Names: Manufactured under the brand name Allegra. It is also known as Terfenadine-COOH, Terfenadine carboxylate, Terfenadine acid metabolite, Fexofenadine hydrochloride, Fexofendine, Carboxyterfenadine.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
Dosing and Administration
Seasonal Allergic Rhinitis
Adults and Children 12 Years and Older: The recommended dose of ALLEGRA is 60 mg twice daily, or 180 mg once daily.
Children 6 to 11 Years: The recommended dose of ALLEGRA is 30 mg twice daily.
Chronic Idiopathic Urticaria
Adults and Children 12 Years and Older: The recommended dose of ALLEGRA is 60 mg twice daily.
Children 6 to 11 Years: The recommended dose of ALLEGRA is 30 mg twice daily.
FDA Package Insert Resources
Indications, Contraindications, Side Effects, Drug Interactions, etc.
Calculate Creatine Clearance
On line calculator of your patients Cr Cl by a variety of formulas.
Convert pounds to Kilograms
On line calculator of your patients weight in pounds to Kg for dosing estimates.
Publication Resources
Recent articles, WikiDoc State of the Art Review, Textbook Information
Trial Resources
Ongoing Trials, Trial Results
Guidelines & Evidence Based Medicine Resources
US National Guidelines, Cochrane Collaboration, etc.
Media Resources
Slides, Video, Images, MP3, Podcasts, etc.
Patient Resources
Discussion Groups, Handouts, Blogs, News, etc.
International Resources
en Español
FDA Package Insert Resources
Indications
Contraindications
Side Effects
Drug Interactions
Precautions
Overdose
Instructions for Administration
How Supplied
Pharmacokinetics and Molecular Data
FDA label
FDA on Fexofenadine
Return to top
Publication Resources
Most Recent Articles on Fexofenadine
Review Articles on Fexofenadine
Articles on Fexofenadine in N Eng J Med, Lancet, BMJ
WikiDoc State of the Art Review
Textbook Information on Fexofenadine
Return to top
Trial Resources
Ongoing Trials with Fexofenadine at Clinical Trials.gov
Trial Results with Fexofenadine
Return to top
Guidelines & Evidence Based Medicine Resources
US National Guidelines Clearinghouse on Fexofenadine
Cochrane Collaboration on Fexofenadine
Cost Effectiveness of Fexofenadine
Return to top
Media Resources
Powerpoint Slides on Fexofenadine
Images of Fexofenadine
Podcasts & MP3s on Fexofenadine
Videos on Fexofenadine
Return to top
Patient Resources
Patient Information from National Library of Medicine
Patient Resources on Fexofenadine
Discussion Groups on Fexofenadine
Patient Handouts on Fexofenadine
Blogs on Fexofenadine
Fexofenadine in the News
Fexofenadine in the Marketplace
Return to top
International Resources
Fexofenadine en Español
Return to top
The content of this page is taken from the FDA package insert for this drug and should not be edited.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
